Chronic Liver Disease (CLD), Fibrosis of Liver
Conditions
Keywords
chronic liver disease, fibrosis
Brief summary
Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.
Interventions
OTHERBlood draw for biomarkers
EDTA tube Blood draw for biomarkers
Sponsors
Universitair Ziekenhuis Brussel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18y * Chronic liver disease: alcohol, metabolic dysfunction associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease and hemochromatosis
Exclusion criteria
* \<18y * Acute hepatitis * Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| correlation of biomarkers in blood and fibrosis stage of liver | Day 1 of the study | correlation of biomarkers in blood and fibrosis stage of the liver (comparison with: transient elastography, fib4, APRI and liver biopsy if possible) |
Countries
Belgium
Contacts
CONTACTSilke François
Outcome results
None listed